BB Biotech AG

Type: Company

Name: BB Biotech AG (BB BIOTECH AG)

Nationality: Switzerland

Fact Sheet: Fact Sheet for BB Biotech AG

First Reported 11/16/2009 - Updated 11/16/2009 - 1 Documents

Form 13F-HR BB BIOTECH AG For: Sep 30

Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++13F-HR+++++BB+BIOTECH+AG+++++++++++++For%3A+Sep+30/5112941.html for the full story. ... [Street Insider - 11/16/2009]

Entities: BB Biotech AG

First Reported 11/02/2009 - Updated 11/02/2009 - 2 Documents (in Health)

Probiodrug gains $54M to back Alzheimer's program

The early-stage German biotech Probiodrug AG won an impressive $54 million in fresh venture capital backing in one of the largest biotech rounds reported this year. The second round was led by BB Biotech and Edmond de Rothschild Investment Partners with ... [FierceBiotech - 11/02/2009]

Entities: Alzheimer's Disease, BB Biotech AG, Biotechnology, TVM Capital GmbH, HBM Bioventures

First Reported 11/02/2009 - Updated 11/02/2009 - 1 Documents

Biogen Idec

Probiodrug Raises $53 Million

LONDON (Reuters) - Privately held Probiodrug of Germany has raised more than 36 million euros ($53 million) to fund its work into Alzheimer’s disease in one of the year’s biggest fund-raisings by an unlisted biotech company.The group said on Monday it ... [Private Equity HUB - 11/02/2009]

Entities: Alzheimer's Disease, BB Biotech AG, Ben Hirschler, Simon Jessop, Biogen Idec

First Reported 11/02/2009 - Updated 11/02/2009 - 1 Documents (in Biology)

Probiodrug AG Closes Series B Financing Round Exceeding $54 Million

Halle/Saale, November 2nd, 2009 -- Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer's disease, today announced the ... [BioSpace - 11/02/2009]

Entities: BB Biotech AG, Enzyme, Germany, Biogen Idec, Biotechnology

First Reported 06/18/2009 - Updated 06/18/2009 - 1 Documents

Total voting rights: Disclosure pursuant to article 26a WpHG as at June 18, 2009

Pursuant to article 26a WpHG BB BIOTECH AG, Vordergasse 3, 8200 Schaffhausen, Switzerland hereby announces that the new number of voting rights amounts to 18 225 000. The new number of voting rights is effective as at June 16, 2009. For further information ... [HUGIN Online - 06/18/2009]

Entities: Bellevue Asset Management, BB Biotech AG, Schaffhausen (Switzerland)

First Reported 07/30/2009 - Updated 07/30/2009 - 1 Documents (in Biotechnology)

Novo Nordisk

BB BIOTECH: Positive development thanks to Genentech and Vertex participations

During 1H 2009, BB BIOTECH's share price appreciated by 4.2% (in CHF, including dividend), while BB BIOTECH's Net Asset Value (NAV) is flat since the beginning of the year. BB BIOTECH's performance during 1H 2009 was in line with the performance of the ... [HUGIN Online - 07/30/2009]

Entities: BB Biotech AG, Novo Nordisk, Vertex

First Reported 08/27/2009 - Updated 08/27/2009 - 1 Documents

Bellevue Group - substantial expansion of asset management activities with a distinct profile

Bellevue Group has steadfastly implemented the strategic expansion of its asset management activities announced earlier this year. As a specialized asset management boutique focused on investing in healthcare stocks, 'new markets' and selected stock-market ... [HUGIN Online - 08/27/2009]

Entities: Bellevue Group AG, Bellevue Asset Management, Luxemburg (Luxembourg), Portfolio Manager

First Reported 09/22/2009 - Updated 09/22/2009 - 1 Documents (in Biotechnology)

Change in BB BIOTECH Management Team

Bellevue Asset Management AG, the designated management company for BB BIOTECH AG, acting in consultation with BB BIOTECH AG's Board of Directors, has appointed Elhan Kosar and Dr. Daniel Koller Co-Managers of the Management Team of BB BIOTECH, effective ... [HUGIN Online - 09/22/2009]

Entities: BB Biotech AG, Bellevue Asset Management, Management Team, Biotechnology

Quotes

Elhan Kosar from BB Biotech stated: "We are very pleased to announce our significant investment in Probiodrug, and commitment to a long-term partnership with the Company. Following the earlier scientific and commercial success of Probiodrug in the DP4 area, we are impressed with the Companyâ€™s innovation and expertise in drug discovery and development applied to a novel target, glutaminyl cyclase (QC). The role of QC in Alzheimerâ€™s disease (AD) and other inflammatory diseases was discovered and comprehensively IP protected by Probiodrug. We believe that Probiodrugâ€™s pioneering scientific approach targeting QC in Alzheimerâ€™s disease has potential to bring a breakthrough treatment to this therapeutic area of great unmet need.â€"

Probiodrug AG Closes Series B Financing Round Exceeding $54 Million [BioSpace - 11/02/2009]

...s disease and other inflammatory diseases was discovered and comprehensively IP-protected by Probiodrug,' said Elhan Kosar from BB Biotech. "We believe that Probiodrug's pioneering scientific approach targeting QC in Alzheimer s disease has potential to bring a breakthrough treatment to this therapeutic area of great unmet need." The German developer is also pursuing new programs for inflammatory diseases...

Probiodrug gains $54M to back Alzheimer's program [FierceBiotech - 11/02/2009]

Log in to Silobreaker

Advanced Search Options

BB Biotech AG